Perspective Therapeutics, Inc.
CATX
$3.00
$0.072.39%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -77.78% | -81.62% | -43.36% | -44.87% | 5.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -77.78% | -81.62% | -43.36% | -44.87% | 5.23% |
| Cost of Revenue | 49.12% | 155.56% | 69.10% | 79.19% | 92.32% |
| Gross Profit | -52.22% | -159.95% | -72.66% | -86.65% | -96.30% |
| SG&A Expenses | -10.93% | -15.70% | 10.84% | 39.81% | 33.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.88% | 88.72% | 47.71% | 64.51% | 66.35% |
| Operating Income | -29.54% | -90.63% | -49.52% | -68.54% | -67.87% |
| Income Before Tax | -44.08% | 9.42% | -71.73% | -96.17% | -53.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -44.08% | 6.67% | -71.73% | -96.17% | -53.72% |
| Earnings from Discontinued Operations | -- | -- | -- | 204.90% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.08% | 6.67% | -71.73% | -83.57% | -47.97% |
| EBIT | -29.54% | -90.63% | -49.52% | -68.54% | -67.87% |
| EBITDA | -28.70% | -92.28% | -50.77% | -70.23% | -66.81% |
| EPS Basic | -0.64% | 16.34% | -63.24% | -64.81% | -1.25% |
| Normalized Basic EPS | -0.64% | -96.76% | -63.30% | -76.05% | -5.16% |
| EPS Diluted | -0.64% | 16.34% | -63.24% | -64.81% | -1.25% |
| Normalized Diluted EPS | -0.64% | -96.76% | -63.30% | -76.05% | -5.16% |
| Average Basic Shares Outstanding | 43.18% | 15.39% | 5.19% | 11.38% | 46.15% |
| Average Diluted Shares Outstanding | 43.18% | 15.39% | 5.19% | 11.38% | 46.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |